EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

Eleonora Gariazzo iD, Francesca Colamartini, Ornella Cantale, Andrea Mogavero, Antonio Vitale, Luca Romano, Marianna Peroni, Erika Rijavec, Marco Banini, Sofia Mazzoni, Mirko Montrone, Giulia Pasello iD und 38 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag285 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Eleonora Gariazzo und 49 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, PG 06156, Italy. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although rebiopsy at progression on osimertinib is recommended for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), its real-world impact on clinical outcomes remains unclear. Rebiopsy on Osi is a multicenter, retrospective study assessing rebiopsy patterns, resistance mechanisms, and their impact on second-line treatment choices and outcomes in routine clinical practice.

Methods

A total of 457 patients with advanced NSCLC harboring a common EGFR mutation (exon 19 deletion or L858R) who progressed on first-line osimertinib were identified from the Italian ATLAS registry. Patients were stratified according to rebiopsy status (tissue and/or plasma-based next-generation sequencing) and receipt of biomarker-driven adaptive second-line therapy.

Results

Rebiopsy was performed in 206 patients (45.1%), predominantly via tissue sampling (66.2%). A resistance mechanism was identified in 80 cases (38.8%), with higher detection rates with tissue rebiopsy (46.6%) than with liquid biopsy (13.5%). MET amplification/overexpression emerged as the most frequent actionable resistance mechanism. Among 239 patients treated with second-line therapy, 39 (16.3%) received adaptive treatment, including 29 of 39 patients (74.3%) with MET amplification/overexpression who were treated with a MET-TKI-based regimen. Median progression-free survival (PFS) and overall survival (OS) were longer with adaptive therapy (7.3 and 14.1 months) than with rebiopsy without treatment adaptation (6.5 and 12.2 months) or no rebiopsy (5.1 and 8.2 months).

Conclusion

In real-world practice, rebiopsy identifies a resistance mechanism in slightly more than one third of patients, with actionable MET amplification/overexpression accounting for approximately one fifth of cases. Biomarker-driven adaptive therapy may improve clinical outcomes, supporting the implementation of rebiopsy in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansIndolesPyrimidinesFemaleErbB ReceptorsMutationMaleRetrospective StudiesAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

EGFR-mutant NSCLCMET amplificationosimertinib resistance mechanismspost-osimertinib therapyreal-world studytumor rebiopsy

Substanzen

IndolesosimertinibAcrylamidesAniline CompoundsPyrimidinesErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, PG 06156, Italy.
  • Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, TO 10043, Italy.
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, 00168, Italy.
  • Department of Medicine and Surgery, University of Parma, Parma, 43121, Italy.
  • Division of Medical Oncology, ASST dei Sette Laghi, Varese, VA 2100, Italy.
  • Department of Experimental and Clinical Biomedical Sciences "Mario Serio," University of Florence , Florence, FI 51134, Italy.

ORCID-Profile: Eleonora Gariazzo, Giulia Pasello, Giacomo Pelizzari, Tiziana Vavalà, Maria Simona Pino, Luana Calabrò, Daniele Pozzessere, Francesco Grossi, Marcello Tiseo, Emilio Bria

Zitieren

APA

Gariazzo, E., Colamartini, F., Cantale, O., Mogavero, A., Vitale, A., Romano, L., Peroni, M., Rijavec, E., Banini, M., Mazzoni, S., Montrone, M., Pasello, G., Veccia, A., Ogliari, F. R., Leo, S., Cortinovis, D., Delmonte, A., Belluomini, L., La Cava, G., …, & Metro, G. (2026). EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study). The Oncologist. https://doi.org/10.1093/oncolo/oyag285

Vancouver

Gariazzo E, Colamartini F, Cantale O, Mogavero A, Vitale A, Romano L, et al. EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study). The Oncologist. 2026. doi:10.1093/oncolo/oyag285

BibTeX
@article{Gariazzo2026,
  author = {Gariazzo, Eleonora and Colamartini, Francesca and Cantale, Ornella and Mogavero, Andrea and Vitale, Antonio and Romano, Luca and Peroni, Marianna and Rijavec, Erika and Banini, Marco and Mazzoni, Sofia and Montrone, Mirko and Pasello, Giulia and Veccia, Antonello and Ogliari, Francesca Rita and Leo, Silvana and Cortinovis, Diego and Delmonte, Angelo and Belluomini, Lorenzo and La Cava, Giulia and Meoni, Giulia and Sini, Claudio and Delcuratolo, Marco Donatello and Bettini, Anna and Pagano, Maria and Genova, Carlo and Russo, Alessandro and Pelizzari, Giacomo and Tondulli, Luca and Sergi, Concetta and Roca, Elisa and Bennati, Chiara and Grisanti, Salvatore and Stanzione, Brigida and Mariotti, Sabrina and Vavalà, Tiziana and Soto Parra, Hector and Ortega, Cinzia and Pignataro, Daniele and Lacidogna, Gaetano and Pino, Maria Simona and Chiari, Rita and Calabrò, Luana and Pozzessere, Daniele and Masini, Silvia and Gelibter, Alain and Scotti, Vieri and Grossi, Francesco and Tiseo, Marcello and Bria, Emilio and Metro, Giulio},
  title = {EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag285}
}
Kostenlos starten →